Alcoholic Hepatitis Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight

The market size of Alcoholic Hepatitis is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as (List of Companies)

[Nevada, United States] - DelveInsight's "Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Alcoholic Hepatitis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Alcoholic Hepatitis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Alcoholic Hepatitis Market Report:
The Alcoholic Hepatitis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In September, 2024: Durect announced that they are introducing a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
In July, 2024: Intercept Pharmaceuticals announced that the purpose of their clinical trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
As per Basra and Anand (2011), since up to 35% of alcoholics are estimated to have AH, the number of AH patients in the United States may be nearly 5 million and in Italy about 500,000.
Doshi et al. (2020) performed a retrospective cohort study using the State Inpatient Databases from Florida, Massachusetts, New York, and Washington from 2010-2014. The study included patients aged 20-79 years admitted with AH. Among 56,973 unique individuals with AH, the majority were male (39,702; 69.7%)
Naveau et al. (1997) studied 1,604 French alcoholic patients. According to the liver biopsies, 194 patients had a normal liver; 402 had steatosis without fibrosis; 281 presented with fibrosis, with or without steatosis; 119 presented with acute alcoholic hepatitis (AAH) without cirrhosis; 232 indicated cirrhosis without AAH; and 179 presented with cirrhosis with AAH.
Key Alcoholic Hepatitis Companies are as follow: DURECT Corporation, Novartis, Gilead Sciences, Vital Therapies, Inc., PharmaKing, Intercept Pharmaceuticals Cellaion SA, Mallinckrodt
Key Alcoholic Hepatitis Therapies are as follow: Larsucosterol, Canakinumab (ACZ885, Ilaris), INT-787, IMM 124-E (Hyperimmune Bovine Colostrum), DUR-928 30 mg, Selonsertib, Prednisolone, INT-787, Orlistat, HepaStem, Terlipressin
Launching multiple stage Alcoholic Hepatitis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Alcoholic Hepatitis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Alcoholic Hepatitis Overview:
Alcoholic hepatitis (AH), as the name suggests, is hepatitis - inflammation of the liver - due to excessive intake of alcohol. Patients typically have a history of heavy alcohol intake, about 8-10 drinks per day. It is usually found in association with fatty liver, an early stage of alcoholic liver disease, and may contribute to fibrosis progression, leading to cirrhosis.

Alcoholic Hepatitis Drugs Uptake and Pipeline Development Activities:
The drugs uptake section examines the rate at which newly launched or upcoming potential drugs are adopted during the study period. This report details the market uptake of these drugs, the adoption rates of therapies by patients, and the sales figures for each drug. It also offers insights into the development activities of the Acne Vulgaris Pipeline, evaluating therapeutic candidates at different stages and highlighting key companies involved.

For more information about Alcoholic Hepatitis companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Alcoholic Hepatitis Therapies and Key Companies:
Larsucosterol (DUR-928): Durect Corporation
Canakinumab (ACZ885, Ilaris): Novartis
INT-787: Intercept Pharmaceuticals
Selonsertib, Prednisolone: Gilead Sciences
HepaStem: Cellaion SA
Terlipressin: Mallinckrodt

Alcoholic Hepatitis Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2019 to 2032. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Alcoholic Hepatitis.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Alcoholic Hepatitis Epidemiology Segmentation:
The Alcoholic Hepatitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Alcoholic Hepatitis Total Prevalence
Alcoholic Hepatitis Prevalent Cases by severity
Alcoholic Hepatitis Gender-specific Prevalence
Alcoholic Hepatitis Diagnosed Cases of Episodic and Chronic

Alcoholic Hepatitis Market Drivers:
Rising Incidence of Alcoholic Hepatitis
Advancements in Research and Development
Increased Awareness and Diagnosis
Growing Investment in Healthcare Infrastructure

Alcoholic Hepatitis Market Barriers:
Limited Awareness in Emerging Markets
Stigma Associated with Alcohol Use
Challenges in Patient Compliance

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Alcoholic Hepatitis Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Alcoholic Hepatitis Companies: DURECT Corporation, Novartis, Gilead Sciences, Vital Therapies, Inc., PharmaKing, Intercept Pharmaceuticals Cellaion SA, Mallinckrodt
Key Alcoholic Hepatitis Therapies: Larsucosterol, Canakinumab (ACZ885, Ilaris), INT-787, IMM 124-E (Hyperimmune Bovine Colostrum), DUR-928 30 mg, Selonsertib, Prednisolone, INT-787, Orlistat, HepaStem, Terlipressin
Alcoholic Hepatitis Therapeutic Assessment: Current marketed and emerging therapies
Alcoholic Hepatitis Market Dynamics: Alcoholic Hepatitis Market drivers and Alcoholic Hepatitis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Alcoholic Hepatitis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Alcoholic Hepatitis market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Executive Summary of Alcoholic Hepatitis
3. Competitive Intelligence Analysis for Alcoholic Hepatitis
4. Alcoholic Hepatitis: Market Overview at a Glance
5. Alcoholic Hepatitis: Disease Background and Overview
6. Patient Journey
7. Alcoholic Hepatitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Alcoholic Hepatitis Unmet Needs
10. Key Endpoints of Alcoholic Hepatitis Treatment
11. Alcoholic Hepatitis Marketed Products
12. Alcoholic Hepatitis Emerging Therapies
List to be continued in report
13. Alcoholic Hepatitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Alcoholic Hepatitis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.